Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | CETP | P11597 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991959 | 0.98 | TSHR (0.50) | SIGMAR1CETPTSHRS1PR2S1PR4 | |
| SCHEMBL27991950 | 0.93 | TSHR (0.47) | SIGMAR1CETPTSHRS1PR2S1PR4 | |
| SCHEMBL7292178 | 0.85 | TSHR (0.50) | CETPTSHR | |
| SCHEMBL5831422 | 0.84 | TSHR (0.45) | CETPTSHRS1PR2S1PR4S1PR1 | |
| SCHEMBL14890455 | 0.83 | CETP (0.50) | SIGMAR1CETPTSHR | |
| SCHEMBL7331812 | 0.81 | CETP (0.47) | CETPTSHR | |
| SCHEMBL9659049 | 0.81 | KLK8 (0.51) | SIGMAR1CETPTSHRS1PR2S1PR4 | |
| SCHEMBL11125267 | 0.78 | CETP (0.56) | CETP | |
| SCHEMBL5054589 | 0.77 | KCNA3 (0.55) | FDPSHDAC1 | |
| SCHEMBL3975163 | 0.76 | MAPT (0.51) | MAPTRXFP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5574024-A | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | EBETINO FRANK H (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0298553-B1 | METHYLENE PHOSPHONOALKYLPHOSPHINATES, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | Norwich Eaton Pharmaceuticals, Inc. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |